Biomarin Pharmaceuticals
(BMRN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2016 | 09-2016 | 06-2016 | 03-2016 | 12-2015 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 408,330 | 707,349 | 305,969 | 270,453 | 397,040 |
| Marketable Securities | 381,347 | 327,499 | 197,318 | 186,400 | 195,579 |
| Receivables | 215,280 | 215,894 | 214,158 | 180,751 | 164,959 |
| Inventories | 355,126 | 347,420 | 326,556 | 296,979 | 271,683 |
| Other current assets | 61,708 | 68,409 | 61,945 | 58,207 | 60,378 |
| TOTAL | $1,421,791 | $1,666,571 | $1,105,946 | $992,790 | $1,089,639 |
| Non-Current Assets | |||||
| PPE Net | 798,768 | 729,836 | 724,494 | 716,916 | 704,207 |
| Investments And Advances | 572,711 | 362,956 | 201,620 | 314,404 | 425,652 |
| Intangibles | 750,819 | 758,426 | 766,005 | 1,374,271 | 881,035 |
| Other Non-Current Assets | 479,601 | 324,449 | 289,239 | 268,612 | 628,835 |
| TOTAL | $2,601,899 | $2,175,667 | $1,981,358 | $2,674,203 | $2,639,729 |
| Total Assets | $4,023,690 | $3,842,238 | $3,087,304 | $3,666,993 | $3,729,368 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 22,478 | 22,460 | 24,420 | N/A | N/A |
| Accounts payable and accrued liabilities | 416,832 | 354,875 | 340,160 | 388,011 | 445,457 |
| TOTAL | $439,310 | $377,335 | $364,580 | $388,011 | $445,457 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 818,105 | 819,095 | 805,148 | 845,219 | 739,537 |
| TOTAL | $818,105 | $819,095 | $805,148 | $988,746 | $883,064 |
| Total Liabilities | $1,257,415 | $1,196,430 | $1,169,728 | $1,376,757 | $1,328,521 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 172,867 | 171,987 | 163,466 | 162,322 | 161,591 |
| Common Shares | 173 | 173 | 164 | 163 | 162 |
| Retained earnings | -1,520,506 | -1,573,068 | -1,530,271 | -1,106,711 | -1,021,569 |
| Other shareholders' equity | -1,505 | -12,811 | -10,441 | -13,513 | 7,417 |
| TOTAL | $2,766,275 | $2,645,808 | $1,917,576 | $2,290,236 | $2,400,847 |
| Total Liabilities And Equity | $4,023,690 | $3,842,238 | $3,087,304 | $3,666,993 | $3,729,368 |